| Autor: |
Amandeep Kaur, Alexandra E. Rojek, Emily Symes, Mariam T. Nawas, Anand A. Patel, Jay L. Patel, Payal Sojitra, Barina Aqil, Madina Sukhanova, Megan E. McNerney, Leo P. Wu, Aibek Akmatbekov, Jeremy Segal, Melissa Y. Tjota, Sandeep Gurbuxani, Jason X. Cheng, Su-Yeon Yeon, Harini V. Ravisankar, Carrie Fitzpatrick, Angela Lager, Michael W. Drazer, Caner Saygin, Pankhuri Wanjari, Panagiotis Katsonis, Olivier Lichtarge, Jane E. Churpek, Sharmila B. Ghosh, Ami B. Patel, Madhu P. Menon, Daniel A. Arber, Peng Wang, Girish Venkataraman |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-11 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2044-5385 |
| DOI: |
10.1038/s41408-024-01077-9 |
| Popis: |
Abstract Current therapies for high-grade TP53-mutated myeloid neoplasms (≥10% blasts) do not offer a meaningful survival benefit except allogeneic stem cell transplantation in the minority who achieve a complete response to first line therapy (CR1). To identify reliable pre-therapy predictors of complete response to first-line therapy (CR1) and outcomes, we assembled a cohort of 242 individuals with TP53-mutated myeloid neoplasms and ≥10% blasts with well-annotated clinical, molecular and pathology data. Key outcomes examined were CR1 & 24-month survival (OS24). In this elderly cohort (median age 68.2 years) with 74.0% receiving frontline non-intensive regimens (hypomethylating agents +/- venetoclax), the overall cohort CR1 rate was 25.6% (50/195). We additionally identified several pre-therapy factors predictive of inferior CR1 including male gender (P = 0.026), ≥2 autosomal monosomies (P 25% (P = 0.002), TP53 splice junction mutations (P = 0.007) and antecedent treated myeloid neoplasm (P = 0.001). In addition, mutations/deletions in CUX1, U2AF1, EZH2, TET2, CBL, or KRAS (‘EPI6’ signature) predicted inferior OS24 (HR = 2.0 [1.5–2.8]; P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full text from SpringerLink